CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.
about
Endocannabinoid signaling in female reproductionCannabis and psychosis/schizophrenia: human studiesEndocannabinoids in the retina: from marijuana to neuroprotectionAnandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.The endocannabinoid system as a target for the treatment of neurodegenerative disease.Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.The role of endocannabinoids in pain modulation.Endocannabinoid signalling in innate and adaptive immunity.Microbial infections, immunomodulation, and drugs of abuse.Multiple actions of anandamide on neonatal rat cultured sensory neurones.The therapeutic potential of cannabis in multiple sclerosis.Cannabinoids and cancer: pros and cons of an antitumour strategy.Silencing or amplification of endocannabinoid signaling in blastocysts via CB1 compromises trophoblast cell migrationNew anti-inflammatory agents to reduce atherosclerosis.Cannabinoid receptor signaling regulates liver development and metabolism.Aspects of endocannabinoid signaling in periimplantation biologyThe endocannabinoid system in brain reward processesCyclooxygenase-2 in synaptic signaling.Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces heme oxygenase 1 transcription in breast cancer cellsEndocannabinoid-mediated control of synaptic transmission.Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry.Signal transduction via cannabinoid receptors.The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects.Neuropathology of substance use disorders.Dendritic Cell Regulation by Cannabinoid-Based DrugsCannabinoid signaling in health and disease.Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2A cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway.Towards a therapeutic use of selective CB2 cannabinoid receptor ligands for atherosclerosis.Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells.Cannabinoid-like anti-inflammatory compounds from flax fiber.Endocannabinoids in the intact retina: 3 H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide.PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons.CB1 Receptors Mediated Inhibition of ATP-Induced [Ca(2+)]i Increase in Cultured Rat Spinal Dorsal Horn Neurons.CB1 and CB2 Receptor Pharmacology.Mechanisms of Neuronal Silencing After Cortical Spreading Depression.Expression of endocannabinoid synthetic enzyme mRnas is correlated with cannabinoid 1 receptor mRNA in the mouse brain.ω-Imidazolyl- and ω-Tetrazolylalkylcarbamates as Inhibitors of Fatty Acid Amide Hydrolase: Biological Activity and in vitro Metabolic Stability.Anandamide inhibits oxidative phosphorylation in isolated liver mitochondria.Endocannabinoids and Human Sperm Cells.Retrograde endocannabinoid inhibition of goldfish retinal cones is mediated by 2-arachidonoyl glycerol
P2860
Q24599033-2BEE268D-B0F6-4050-9967-4FA275409E81Q24628837-E4B8E936-3974-4007-A682-E080CB837523Q24656049-92639A2E-5461-4F0F-B5D3-07B9DCB98F9AQ33526286-D14C35B5-B547-440E-8B3C-03A5F384CDCFQ34098196-55331A41-6512-4A69-880D-F3EEC3502160Q34139377-DE85DF89-7ACB-4F39-93F6-29D1998A13E0Q34320270-F77D2337-0AD8-44DB-8A00-037283622C17Q34458059-025D855A-562C-4365-8748-EEDFBD0A85F5Q34926928-E00EA745-873B-4348-B404-0FD7716801E9Q35047032-96168BF1-FE67-480C-82EA-DD85712A2F75Q35094657-BE49A88E-E2DB-45E2-9B4A-A1DF53FE4CD4Q35100892-A4064C6D-F808-4C95-B57E-334BA6312679Q36234840-EE2E98AE-068D-422E-A1B1-CF12E13ED024Q36576558-7F1D9EFE-D0F2-4D0B-A496-3601C88DA808Q36597443-B8426961-32E9-4A59-911E-90174555ACA0Q36731481-54D48DEC-42C8-45BA-8824-8188A4AB725BQ36741861-C19AA619-6929-4B9B-A8C3-3A1978910314Q36922736-2A650148-A8C9-49EA-9909-0D836927CBBEQ37219066-AA4E93B1-4DD2-4F90-841E-52A5FE1FA128Q37363621-595CE691-3BB8-4C95-81B6-22C09513CA62Q37395146-A1F9EC65-4315-45DB-A2D5-23B0182F6155Q37617453-C85EF2E8-A63A-435E-973D-CC30155E0EB4Q38072364-B7B65F09-FF1A-4A0A-8497-629080499C7BQ38167646-764C3363-EBE8-46B3-8E78-85544D827271Q38974441-FABB6EF0-CCF0-421E-8C29-6CBA5C1DD969Q39163671-2FB81D31-79D4-466C-AB9B-CDA5DC54DAF9Q40251961-1E65BBA9-320B-42DB-BE3F-1FFF62FD602BQ40361574-1E0F7BEB-A6B9-460C-B826-15A38D02526AQ40607395-31A6C5F8-89E2-4D1C-ADC9-885AD7B0EF6BQ42653925-E7134C5F-E65B-47A2-9653-1955AB507043Q46936833-69BB2B9F-3C6E-4C52-AD9A-605000704974Q46949449-D5FD1F13-076C-40D2-A8B3-D4D318B55D8DQ47614713-86421429-2B4E-4A48-B2E0-34755616B1CFQ47926400-A54B6963-AE3C-49CE-856D-DA80A533DEA1Q48067004-AB9D21FF-BC79-42F0-AFA0-CF3B6F9D0DA8Q48151037-1A6C35A9-3AE4-4038-A28A-47075762A53CQ52890709-5543E02F-B159-496C-ACDB-29FD6D53C38AQ54624346-6739AE83-3D8E-4DD2-B29D-AB01F4966E54Q55506597-EB4E6E09-8422-4463-9119-47F315CCB8F7Q57364805-DA78050D-0736-4708-8E24-76B51F7F7F9D
P2860
CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.
@ast
CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.
@en
type
label
CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.
@ast
CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.
@en
prefLabel
CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.
@ast
CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.
@en
P356
P1476
CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.
@en
P2093
Sean D McAllister
P304
P356
10.1054/PLEF.2001.0344
P577
2002-02-01T00:00:00Z